Histogenics files IPO for $65M

Histogenics, a biotech company focused on developing an implantable tissue repair platform for cartilage damage to the knee, filed with the U.S. Securities and Exchange Commission to raise up to $65 million in an initial public offering, according to a Renaissance Capital IPO News report.

The company plans to use the funds to develop and complete clinical trials for its regenerative medicine platform, NeoCart. Histogenics plans to list on the NASDAQ under the symbol HSGX. Cowen & Company, Needham and Canaccord Genuity are the joint bookrunners on the deal. No pricing terms were disclosed.

Histogenics files IPO for $65M

More articles on devices:

Next Up in Orthopedic

'The FFS model is a hamster wheel': What orthopedic surgeons told us in March

Dr. Leo Spector on reshaping payer models and betting on value

Robotic knee surgeries linked to higher complication rates: Study

More articles on devices:

Key Trends Impacting FQHCs in 2026 – and How Organizations Can Respond

Next Up in Orthopedic

'The FFS model is a hamster wheel': What orthopedic surgeons told us in March

Dr. Leo Spector on reshaping payer models and betting on value

Robotic knee surgeries linked to higher complication rates: Study

Join the spine leaders & surgeons who start their day with Becker's